Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer

Hiroyuki Yasuda, Eunyoung Park, Cai Hong Yun, Natasha J. Sng, Antonio R. Lucena-Araujo, Wee Lee Yeo, Mark S. Huberman, David W. Cohen, Sohei Nakayama, Kota Ishioka, Norihiro Yamaguchi, Megan Hanna, Geoffrey R. Oxnard, Christopher S. Lathan, Teresa Moran, Lecia V. Sequist, Jamie E. Chaft, Gregory J. Riely, Maria E. Arcila, Ross A. SooMatthew Meyerson, Michael J. Eck, Susumu S. Kobayashi, Daniel B. Costa

Research output: Contribution to journalArticle

190 Citations (Scopus)

Abstract

Epidermal growth factor receptor (EGFR) gene mutations (G719X, exon 19 deletions/insertions, L858R, and L861Q) predict favorable responses to EGFR tyrosine kinase inhibitors (TKIs) in advanced non-small cell lung cancer (NSCLC). However, EGFR exon 20 insertion mutations (∼10% of all EGFR mutations) are generally associated with insensitivity to available TKIs (gefitinib, erlotinib, and afatinib). The basis of this primary resistance is poorly understood. We studied a broad subset of exon 20 insertion mutations, comparing in vitro TKI sensitivity with responses to gefitinib and erlotinib in NSCLC patients, and found that most are resistant to EGFR TKIs. The crystal structure of a representative TKI-insensitive mutant (D770-N771insNPG) reveals an unaltered adenosine triphosphate-binding pocket, and the inserted residues form a wedge at the end of the C helix that promotes the active kinase conformation. Unlike EGFR-L858R, D770-N771insNPG activates EGFR without increasing its affinity for EGFR TKIs. Unexpectedly, we find that EGFR-A763-Y764insFQEA is highly sensitive to EGFR TKIs in vitro, and patients whose NSCLCs harbor this mutation respond to erlotinib. Analysis of the A763-Y764insFQEA mutant indicates that the inserted residues shift the register of the C helix in the N-terminal direction, altering the structure in the region that is also affected by the TKI-sensitive EGFR-L858R. Our studies reveal intricate differences between EGFR mutations, their biology, and their response to EGFR TKIs.

Original languageEnglish
Article number216ra177
JournalScience Translational Medicine
Volume5
Issue number216
DOIs
Publication statusPublished - 2013 Dec 18

Fingerprint

Insertional Mutagenesis
Epidermal Growth Factor Receptor
Exons
Lung Neoplasms
Protein-Tyrosine Kinases
Mutation
Non-Small Cell Lung Carcinoma
erbB-1 Genes
Phosphotransferases
Adenosine Triphosphate

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. / Yasuda, Hiroyuki; Park, Eunyoung; Yun, Cai Hong; Sng, Natasha J.; Lucena-Araujo, Antonio R.; Yeo, Wee Lee; Huberman, Mark S.; Cohen, David W.; Nakayama, Sohei; Ishioka, Kota; Yamaguchi, Norihiro; Hanna, Megan; Oxnard, Geoffrey R.; Lathan, Christopher S.; Moran, Teresa; Sequist, Lecia V.; Chaft, Jamie E.; Riely, Gregory J.; Arcila, Maria E.; Soo, Ross A.; Meyerson, Matthew; Eck, Michael J.; Kobayashi, Susumu S.; Costa, Daniel B.

In: Science Translational Medicine, Vol. 5, No. 216, 216ra177, 18.12.2013.

Research output: Contribution to journalArticle

Yasuda, H, Park, E, Yun, CH, Sng, NJ, Lucena-Araujo, AR, Yeo, WL, Huberman, MS, Cohen, DW, Nakayama, S, Ishioka, K, Yamaguchi, N, Hanna, M, Oxnard, GR, Lathan, CS, Moran, T, Sequist, LV, Chaft, JE, Riely, GJ, Arcila, ME, Soo, RA, Meyerson, M, Eck, MJ, Kobayashi, SS & Costa, DB 2013, 'Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer', Science Translational Medicine, vol. 5, no. 216, 216ra177. https://doi.org/10.1126/scitranslmed.3007205
Yasuda, Hiroyuki ; Park, Eunyoung ; Yun, Cai Hong ; Sng, Natasha J. ; Lucena-Araujo, Antonio R. ; Yeo, Wee Lee ; Huberman, Mark S. ; Cohen, David W. ; Nakayama, Sohei ; Ishioka, Kota ; Yamaguchi, Norihiro ; Hanna, Megan ; Oxnard, Geoffrey R. ; Lathan, Christopher S. ; Moran, Teresa ; Sequist, Lecia V. ; Chaft, Jamie E. ; Riely, Gregory J. ; Arcila, Maria E. ; Soo, Ross A. ; Meyerson, Matthew ; Eck, Michael J. ; Kobayashi, Susumu S. ; Costa, Daniel B. / Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. In: Science Translational Medicine. 2013 ; Vol. 5, No. 216.
@article{86ce4d3796ed45b09475a39995736b8e,
title = "Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer",
abstract = "Epidermal growth factor receptor (EGFR) gene mutations (G719X, exon 19 deletions/insertions, L858R, and L861Q) predict favorable responses to EGFR tyrosine kinase inhibitors (TKIs) in advanced non-small cell lung cancer (NSCLC). However, EGFR exon 20 insertion mutations (∼10{\%} of all EGFR mutations) are generally associated with insensitivity to available TKIs (gefitinib, erlotinib, and afatinib). The basis of this primary resistance is poorly understood. We studied a broad subset of exon 20 insertion mutations, comparing in vitro TKI sensitivity with responses to gefitinib and erlotinib in NSCLC patients, and found that most are resistant to EGFR TKIs. The crystal structure of a representative TKI-insensitive mutant (D770-N771insNPG) reveals an unaltered adenosine triphosphate-binding pocket, and the inserted residues form a wedge at the end of the C helix that promotes the active kinase conformation. Unlike EGFR-L858R, D770-N771insNPG activates EGFR without increasing its affinity for EGFR TKIs. Unexpectedly, we find that EGFR-A763-Y764insFQEA is highly sensitive to EGFR TKIs in vitro, and patients whose NSCLCs harbor this mutation respond to erlotinib. Analysis of the A763-Y764insFQEA mutant indicates that the inserted residues shift the register of the C helix in the N-terminal direction, altering the structure in the region that is also affected by the TKI-sensitive EGFR-L858R. Our studies reveal intricate differences between EGFR mutations, their biology, and their response to EGFR TKIs.",
author = "Hiroyuki Yasuda and Eunyoung Park and Yun, {Cai Hong} and Sng, {Natasha J.} and Lucena-Araujo, {Antonio R.} and Yeo, {Wee Lee} and Huberman, {Mark S.} and Cohen, {David W.} and Sohei Nakayama and Kota Ishioka and Norihiro Yamaguchi and Megan Hanna and Oxnard, {Geoffrey R.} and Lathan, {Christopher S.} and Teresa Moran and Sequist, {Lecia V.} and Chaft, {Jamie E.} and Riely, {Gregory J.} and Arcila, {Maria E.} and Soo, {Ross A.} and Matthew Meyerson and Eck, {Michael J.} and Kobayashi, {Susumu S.} and Costa, {Daniel B.}",
year = "2013",
month = "12",
day = "18",
doi = "10.1126/scitranslmed.3007205",
language = "English",
volume = "5",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "216",

}

TY - JOUR

T1 - Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer

AU - Yasuda, Hiroyuki

AU - Park, Eunyoung

AU - Yun, Cai Hong

AU - Sng, Natasha J.

AU - Lucena-Araujo, Antonio R.

AU - Yeo, Wee Lee

AU - Huberman, Mark S.

AU - Cohen, David W.

AU - Nakayama, Sohei

AU - Ishioka, Kota

AU - Yamaguchi, Norihiro

AU - Hanna, Megan

AU - Oxnard, Geoffrey R.

AU - Lathan, Christopher S.

AU - Moran, Teresa

AU - Sequist, Lecia V.

AU - Chaft, Jamie E.

AU - Riely, Gregory J.

AU - Arcila, Maria E.

AU - Soo, Ross A.

AU - Meyerson, Matthew

AU - Eck, Michael J.

AU - Kobayashi, Susumu S.

AU - Costa, Daniel B.

PY - 2013/12/18

Y1 - 2013/12/18

N2 - Epidermal growth factor receptor (EGFR) gene mutations (G719X, exon 19 deletions/insertions, L858R, and L861Q) predict favorable responses to EGFR tyrosine kinase inhibitors (TKIs) in advanced non-small cell lung cancer (NSCLC). However, EGFR exon 20 insertion mutations (∼10% of all EGFR mutations) are generally associated with insensitivity to available TKIs (gefitinib, erlotinib, and afatinib). The basis of this primary resistance is poorly understood. We studied a broad subset of exon 20 insertion mutations, comparing in vitro TKI sensitivity with responses to gefitinib and erlotinib in NSCLC patients, and found that most are resistant to EGFR TKIs. The crystal structure of a representative TKI-insensitive mutant (D770-N771insNPG) reveals an unaltered adenosine triphosphate-binding pocket, and the inserted residues form a wedge at the end of the C helix that promotes the active kinase conformation. Unlike EGFR-L858R, D770-N771insNPG activates EGFR without increasing its affinity for EGFR TKIs. Unexpectedly, we find that EGFR-A763-Y764insFQEA is highly sensitive to EGFR TKIs in vitro, and patients whose NSCLCs harbor this mutation respond to erlotinib. Analysis of the A763-Y764insFQEA mutant indicates that the inserted residues shift the register of the C helix in the N-terminal direction, altering the structure in the region that is also affected by the TKI-sensitive EGFR-L858R. Our studies reveal intricate differences between EGFR mutations, their biology, and their response to EGFR TKIs.

AB - Epidermal growth factor receptor (EGFR) gene mutations (G719X, exon 19 deletions/insertions, L858R, and L861Q) predict favorable responses to EGFR tyrosine kinase inhibitors (TKIs) in advanced non-small cell lung cancer (NSCLC). However, EGFR exon 20 insertion mutations (∼10% of all EGFR mutations) are generally associated with insensitivity to available TKIs (gefitinib, erlotinib, and afatinib). The basis of this primary resistance is poorly understood. We studied a broad subset of exon 20 insertion mutations, comparing in vitro TKI sensitivity with responses to gefitinib and erlotinib in NSCLC patients, and found that most are resistant to EGFR TKIs. The crystal structure of a representative TKI-insensitive mutant (D770-N771insNPG) reveals an unaltered adenosine triphosphate-binding pocket, and the inserted residues form a wedge at the end of the C helix that promotes the active kinase conformation. Unlike EGFR-L858R, D770-N771insNPG activates EGFR without increasing its affinity for EGFR TKIs. Unexpectedly, we find that EGFR-A763-Y764insFQEA is highly sensitive to EGFR TKIs in vitro, and patients whose NSCLCs harbor this mutation respond to erlotinib. Analysis of the A763-Y764insFQEA mutant indicates that the inserted residues shift the register of the C helix in the N-terminal direction, altering the structure in the region that is also affected by the TKI-sensitive EGFR-L858R. Our studies reveal intricate differences between EGFR mutations, their biology, and their response to EGFR TKIs.

UR - http://www.scopus.com/inward/record.url?scp=84892631191&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892631191&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.3007205

DO - 10.1126/scitranslmed.3007205

M3 - Article

C2 - 24353160

AN - SCOPUS:84892631191

VL - 5

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 216

M1 - 216ra177

ER -